ALT Altimmune Inc

Altimmune to Participate in Upcoming Investor Conferences

Altimmune to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate and be available for one-on-one meetings at the following investor conferences:

  • Leerink Global Healthcare Conference

    Monday, March 9, 2026 – One-on-one meetings

    Wednesday, March 11, 2026 – Fireside chat at 9:20 a.m. ET
  • Citizens Life Sciences Conference

    Tuesday, March 10, 2026 – One-on-one meetings

    Fireside chat at 2:15 p.m. ET
  • Jefferies Biotech on the Beach Summit

    Wednesday, March 11, 2026 – One-on-one meetings only
  • Barclays 28th Annual Global Healthcare Conference

    Thursday, March 12, 2026 – One-on-one meetings

    Fireside chat at 10:30 a.m. ET

Webcasts of the fireside chats at the Leerink, Citizens and Barclays conferences will be available via the section of the Altimmune website.

Registered investors may request meetings on the dates noted above via their sales contacts at the respective banks.

About Altimmune

Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit .

Follow @Altimmune, Inc. on

Follow @AltimmuneInc on

Investor Contact:

Lee Roth

Burns McClellan

Media Contact:

Real Chemistry

This press release was published by a CLEAR® Verified individual.



EN
02/03/2026

Underlying

ALTAltimmune Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Altimmune Inc

 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Participate in Upcoming Investor Conferences

Altimmune to Participate in Upcoming Investor Conferences GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate and be available for one-on-one meetings at the following investor conferences: Leerink Global Healthcare Conference Monday, March 9, 2026 – One-on-one meetingsWednesday, March 11, 2026 – Fireside chat at 9:20 a.m. ET Citizens Life Sciences Conference Tuesday, March 10, 2026 – One-on-one meetings Fireside cha...

14h / 11m 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Report Fourth Quarter and Full Year 2025 Financial Result...

Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its fourth quarter 2025 financial results on Thursday, March 5, 2026. Altimmune management will host a conference call at 8:30 a.m. ET on March 5 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune’s ...

February 26, 2026 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces Closing of $75 Million Registered Direct Offering ...

Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock GAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17,045,454 shares of its common stock (or pre-funded warrants in lieu thereof) pursuant to a registered direct offering. Th...

January 29, 2026 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces Pricing of $75 Million Registered Direct Offering ...

Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced today that it has entered into a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17,045,454 shares of its common stock (or pre-funded warrants in lieu thereof) pursuant to a registered direct offering. The offering is expected to result in gross procee...

January 28, 2026 1 EN
Free Trial
ALT ALTIMMUNE INC

Altimmune Inc: 1 director

A director at Altimmune Inc bought 5,000 shares at 4.082USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

01/09/26 January 9, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch